Medical Manometry System Market

A ManoScan ESO catheter packs 36 circumferential pressure channels at 1.0 cm spacing into a 4.2 mm tube, giving 432 measurement points that turn a single swallow into a colour pressure map, according to Medtronic’s ManoScan specifications. The Medical Manometry System Market covers the consoles, acquisition modules, analysis software, reusable and single-use catheters, sheaths and service contracts that measure pressure in the pharynx, oesophagus, colon and anorectum. Douglas Insights builds the 2025 figure from studies, not boxes: 2.47 million manometry studies x USD 152.6 of vendor revenue per study = USD 376.9 million, rising to USD 644.9 million by 2035 at a revenue CAGR of 5.52%. On the product side, the FDA cleared GI Bionics’ Fecobionics Anorectal System on 12 February 2025, a probe that adds orientation sensors and a 100 mL bag to classic anorectal pressure testing. The study sits in our diagnostic devices coverage and follows the published research methodology.

Why are constipation and dysphagia referrals behind rising manometry study demand?

Manometry study volumes grow 4.35% a year in our base case, and four referral streams explain the whole figure. They are anorectal testing for constipation and incontinence, oesophageal work-ups for reflux and dysphagia, new motility laboratories in Asia, and longer standardised protocols. Together they lift global studies from 2.47 million in 2025 to about 3.78 million in 2035.

Anorectal referrals contribute 1.62 percentage points, the largest share. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reports that about 16 in 100 US adults have constipation symptoms, rising to 33 in 100 among adults aged 60 and over, and that 7 to 15 in 100 community-dwelling adults have fecal incontinence. A high-resolution anorectal manometry (HRAM) study is the standard way to tell weak sphincters from dyssynergic defecation, so every gastroenterology clinic that adds a pelvic floor service adds manometry volume. Douglas Insights estimates that anorectal studies made up about 31% of the 2025 study count.

Oesophageal work-ups contribute 1.21 points. About 20% of people in the United States have gastroesophageal reflux disease (GERD), according to NIDDK, and patients considered for anti-reflux surgery or treatment of achalasia need high-resolution manometry (HRM) before an operation. Medicare treats esophageal manometry as covered where it is reasonable and necessary for the individual patient under National Coverage Determination 100.4, which keeps the referral route open for older patients.

New laboratories in Asia Pacific and other emerging systems contribute 0.97 points. Every teaching hospital that opens a GI physiology unit buys a console, trains two or three operators and starts a catheter stream, and those units start from a low base of studies per million people. Our regional model gives Asia Pacific 7.74% annual value growth, the fastest of any region.

Longer, standardised protocols contribute 0.55 points. A modern oesophageal study now asks for at least 15 wet swallows plus provocative tests, and the anorectal protocol of the International Anorectal Physiology Working Group (IAPWG), now embedded in Laborie’s Solar software, fixes each step in sequence. More steps mean more catheter time, more repeat studies when a test fails and more software analysis per patient. Each added swallow, repeat attempt and software review also raises the revenue booked per study, which feeds the 1.12% price leg. The four contributions add to 4.35 points, the full volume leg, and the 12 February 2025 Fecobionics clearance shows device makers still betting on new anorectal measurement formats.

What limits anorectal and esophageal manometry uptake outside teaching hospitals?

Three barriers would cut manometry study growth from 4.35% to 2.60% a year in our slower case, removing 1.75 points. The three are thin physician payments for the test, high catheter and console prices, and a shortage of trained GI physiologists who can run and read a study.

Payment removes 0.71 points. Medtronic’s ManoScan coding guide lists 2022 Medicare national averages of USD 234 for an esophageal motility study (CPT 91010) and USD 285 for anorectal manometry (CPT 91122) in the physician office, against USD 499 and USD 272 in the hospital outpatient setting, as shown in the ManoScan reimbursement guide. The same guide states that 91010 and 91122 are not on the Medicare ambulatory surgical center fee schedule, which keeps most studies in hospitals and larger offices.

Equipment price removes 0.62 points. A single reusable solid-state oesophageal catheter can cost more than GBP 10,000 in an NHS purchase, so a small clinic must commit to a high study count before a manometry system pays back. Many community gastroenterology practices refer out instead.

Staffing removes 0.42 points. A manometry study needs a trained operator to place the catheter through the nose or into the rectum, run the protocol and apply a classification scheme. Douglas Insights counts staffing at 0.42 points of lost growth, the slowest constraint to fix, because training takes years while consoles ship in weeks.

Esophageal versus anorectal catheters: which manometry segment earns most?

Esophageal manometry earns most, at 46.4% of 2025 value or USD 174.9 million in our model, because reflux, dysphagia and pre-surgical work-ups send the largest patient stream through HRM catheters. Anorectal manometry follows at 30.7%, and it is the segment that grows fastest to 2035.

Esophageal manometry reaches USD 277.1 million by 2035 at 4.71% a year. Its share is the largest because the installed base of solid-state HRM consoles is oldest in this segment, and each study consumes sheath or catheter value.

Anorectal manometry grows fastest, at 6.97% a year from USD 115.7 million to USD 227.0 million. The reason is the size of the constipation and incontinence pool against how few patients are tested, plus single-use air-charged catheters that remove sterilisation work from small clinics.

Pharyngeal and colonic manometry is valued at USD 32.4 million and grows 6.34% a year to USD 59.9 million. Its share is small because colonic studies stay in tertiary centres, while pharyngeal HRM for swallowing clinics is still building its evidence base.

Software and service contracts accounts for USD 53.9 million and rises 4.13% a year to USD 80.8 million. Service contracts and module replacements follow the console base, so this segment grows slower than catheter-driven lines.

The study also splits manometry demand by technology (Solid-state, Water-perfused, Air-charged) and by end user (Hospitals, Specialty clinics, Ambulatory surgery centers, Academic research institutes).

Where do high-resolution manometry labs cluster, and which region adds studies fastest?

North America leads with USD 147.7 million, or 39.2% of 2025 manometry value, because Medicare-covered motility testing and high catheter prices concentrate spending there. Asia Pacific adds studies fastest, with value growing 7.74% a year as hospitals across the region open GI physiology units.

North America grows 4.83% a year to USD 236.7 million by 2035, driven by pelvic floor referrals and an ageing reflux population.

Europe holds USD 112.3 million in our 2025 model and grows 4.27% a year to USD 170.6 million. NHS trusts buy manometry consoles, modules and catheters through small public tenders, which caps realised prices and slows value growth.

Asia Pacific is valued at USD 80.3 million and reaches USD 169.2 million by 2035, nearly matching Europe. Low studies per million and new teaching hospitals explain the 7.74% rate.

Latin America accounts for USD 20.4 million and grows 5.86% a year to USD 36.1 million. Brazilian centres have published water-perfused HRAM work on a 24-channel Alacer Biomedica system, a cheaper route into anorectal testing for private gastroenterology clinics.

Middle East and Africa is the wildcard: USD 16.2 million in 2025, rising 7.14% a year to USD 32.3 million by 2035. A handful of Gulf hospital projects with GI physiology suites would move that small base more than any other region.

Which manufacturers supply solid-state and air-charged manometry catheters?

Medtronic leads manometry systems with an estimated 37.8% of 2025 value, and the top three manufacturers hold about 77.3%, by Douglas Insights estimates based on catalogue breadth and public tender awards. Laborie and Diversatek follow, with Mui Scientific, Alacer Biomedica, Medspira and GI Bionics in narrower niches.

Medtronic’s position rests on the ManoScan family: the 36-channel ESO catheter, 2.75 mm small-diameter versions, 8- and 12-channel anorectal catheters and a 3D anorectal probe with 256 sensors in 16 regions. Douglas Insights puts the top three manufacturers’ manometry revenue at about USD 291.3 million in 2025.

Laborie built its GI line by buying Medical Measurement Systems (MMS) in 2015 and then launched the Solar Compact System and Solar anorectal manometry catheter on 20 May 2024. The catheter has 10 air-charged sensing balloons plus a distal rectal balloon, and the FDA cleared it as K234107 on 23 April 2024. Laborie’s Solar GI console handles up to 40 pressure channels and applies the London classification automatically.

Diversatek Healthcare, based in Milwaukee, sells the inSIGHT Ultima manometry system, registered with the FDA under product code FFX. Mui Scientific in Toronto makes water-perfused pumps and catheters and runs its own manufacturing, which keeps it in research centres that prefer perfused catheters.

Alacer Biomedica supplies a 24-channel water-perfused system arranged as 6 levels of 4 radial channels, used in the first Brazilian water-perfused HRAM study of 50 patients. Medspira of Minneapolis sells mcompass anorectal devices, and GI Bionics of San Diego entered with the Fecobionics clearance of 12 February 2025, which uses a single-use AR-100 probe, a reusable DH-100 data hub and Fecotracker software.

How much do hospitals pay for a manometry console, catheter and sheath?

NHS buyers paid GBP 60,049.50 for a complete water-perfused HRM system and GBP 10,680 per ManoScan ESO catheter in recent public notices, and those two figures anchor our manometry price bands. Douglas Insights sets blended vendor revenue at USD 152.6 per study in 2025.

Public notices give the realised prices. Shropshire Healthcare Procurement Service bought a Laborie GI high-resolution water-perfused manometry system for GBP 60,049.50 in March 2024. In November 2025 an NHS buyer paid Medtronic GBP 21,360 for two 1286 ManoScan ESO catheters, Sheffield Teaching Hospitals paid GBP 18,060 including VAT for a replacement ManoScan A120 acquisition module from August 2025, and Mersey and West Lancashire Teaching Hospitals paid Laborie GBP 11,738.29 before VAT for 5 boxes of oesophageal and 7 boxes of anorectal catheters in September 2025, or about GBP 978 a box.

Douglas Insights price bands for 2025 run as follows: complete manometry consoles at USD 55,000 to USD 120,000; reusable solid-state oesophageal catheters at USD 11,000 to USD 15,000; and single-use catheter and sheath spend of USD 40 to USD 160 per study. The blended price rises 1.12% a year to about USD 170.6 per study by 2035, as single-use catheters and 3D probes lift the mix.

How do solid-state, water-perfused and air-charged manometry sensors differ in practice?

Solid-state manometry catheters carry 36 or more sensors inside the tube, while air-charged catheters use about 10 small balloons. Water-perfused catheters sit between them, reading pressure through fluid channels to external transducers. Each design sets catheter price, reprocessing work and per-study spend for the motility lab.

Solid-state catheters cost the most but give the densest pressure map, which is why tertiary manometry centres favour them. Water-perfused systems, such as Alacer Biomedica’s 24-channel model, use cheaper catheters and suit price-sensitive labs. Air-charged single-use catheters trade some resolution for no reprocessing, which suits busy pelvic floor clinics.

Did Chicago Classification v4.0 add swallows to every esophageal manometry study?

Chicago Classification version 4.0 asks for 10 supine and at least 5 upright 5 mL wet swallows, plus a multiple rapid swallow and a 200 mL rapid drink challenge. Each esophageal manometry study therefore runs in two positions with provocative tests, which adds catheter time and repeat studies.

The Chicago Classification version 4.0 paper, published in Neurogastroenterology and Motility in 2021, was written by 52 experts from 20 countries across six motility societies. For ManoScan systems it sets an abnormal integrated relaxation pressure (IRP) at 15 mmHg or more supine and 12 mmHg or more upright. Douglas Insights expects about 0.55 points of annual volume growth from protocol changes like this one, because every extra position and test adds repeat manometry studies when patients cannot complete them.

How many constipated and incontinent patients reach an anorectal manometry test?

Only a small share reaches a test, although about 16 in 100 US adults have constipation symptoms and 7 to 15 in 100 have fecal incontinence. Anorectal manometry made up roughly 31% of our 2.47 million global studies in 2025, and that gap is the main reason the segment grows fastest.

The recto-anal inhibitory reflex (RAIR), squeeze pressure and rectal sensation are core anorectal manometry readings, and both new anorectal devices cleared since 2024, Laborie’s Solar catheter and the Fecobionics probe, assess the RAIR. Readers sizing the treatment side of the same patient pool should see our Bowel Stimulators Market report, where sacral and tibial stimulation are counted separately from the diagnostic test.

What if 3D anorectal probes and AI swallow analysis reset the 2035 manometry outlook?

The base case reaches USD 644.9 million by 2035 on 4.35% volume and 1.12% price growth. The slower case on 2.60% and 0.40% gives USD 507.0 million, and the faster case on 5.90% and 1.70% gives USD 791.4 million. Anorectal adoption decides which manometry path holds.

In the faster case, sensor-rich probes such as the device behind the 12 February 2025 Fecobionics clearance and automated swallow analysis cut reading time, so clinics run more studies per operator and pay more per study. In the slower case, payment pressure keeps manometry in hospitals. Volume is the lever: at 5.35% study growth instead of 4.35%, the 2035 manometry value would be USD 709.5 million, or USD 64.6 million higher. Our 5.52% revenue CAGR sits near the lower half of published forecasts, which run from about 4.8% to 8.4% a year, because we model studies rather than shipments.

Which FDA 510(k) and CE marking rules govern manometry catheter launches?

US manometry systems and catheters are Class II devices under 21 CFR 876.1725, cleared through 510(k) under product codes such as KLA and FFX. In Europe they need CE marking under the Medical Device Regulation (MDR), whose extended transition runs to 31 December 2027 or 2028.

Each new manometry catheter needs its own 510(k): Laborie’s Solar anorectal catheter was compared with a 4-balloon predicate cleared as K022023, and the Fecobionics probe was cleared as substantially equivalent under the same regulation. In Europe, Regulation (EU) 2023/607 extended the MDR transition, which gives smaller suppliers time to recertify legacy consoles. For buyers comparing adjacent GI hardware, our Hospital Endoscopy Equipment Market study covers the scopes that usually precede a manometry referral.

Douglas Exclusive: the Manometry Catheter Spend-per-Study Ledger

The Manometry Catheter Spend-per-Study Ledger is a Douglas Insights model built from 12 inputs. Every input is a published figure: 4 NHS purchase notices, 5 Medicare payment rates from the ManoScan guide and 3 catheter specifications from Medtronic, Laborie and the FDA. It sets what a lab spends on catheters per manometry study against what the study earns.

The ledger counts catheter and console spend per manometry study under two stated Douglas Insights assumptions, a 200-study life for a reusable solid-state catheter and 400 studies a year on a console. Its finding: catheter spend of GBP 53.40 per study is more than twice the GBP 21.45 console charge, so the catheter, not the console, decides whether a small lab can afford high-resolution manometry. A single ManoScan catheter costs 17.8% of a whole water-perfused system.

How does our methodology convert 2.47 million manometry studies into revenue?

Our methodology multiplies 2.47 million manometry studies by USD 152.6 of vendor revenue per study to reach USD 376.9 million, then grows studies at 4.35% and price at 1.12% to USD 644.9 million by 2035. The regional and segment builds were each added up on their own and land on the same total.

The model covers 5 regions, with the United States and the United Kingdom as the 2 price-anchor countries, and uses 41 data points: 12 tender and payment figures, 9 device specifications, 6 prevalence figures, 3 published growth rates and 11 Douglas Insights study-count and price assumptions. Regional values sum to USD 376.9 million in 2025 and USD 644.9 million in 2035. Segment 2035 values sum to USD 644.8 million, within 0.1% of the top-down figure. As a cross-check, the top three manufacturers’ estimated revenue of USD 291.3 million equals 77.3% of the market.

Sources

1. Medtronic ManoScan ESO high resolution manometry system specifications (2025)
2. US Food and Drug Administration 510(k) K242666 Fecobionics Anorectal System (2025)
3. US Food and Drug Administration 510(k) K234107 Solar Anorectal Manometry Catheter (2024)
4. Medtronic ManoScan ESO and AR reimbursement coding guide (2022)
5. Laborie Solar Compact System and Solar anorectal catheter launch (2024)
6. UK Contracts Finder GI high-resolution manometry system award (2024)
7. UK Find a Tender Oesophageal and anorectal manometry catheters award (2025)
8. Neurogastroenterology and Motility (eScholarship copy) Chicago Classification version 4.0 (2021)
9. NIDDK Constipation definition and facts (2025)
10. Centers for Medicare and Medicaid Services NCD 100.4 Esophageal Manometry (2025)